Member Info for RayPointer

These are exciting times if Mark is considering creating a custard pie subsidiary

Notpotalot post recommended.

I just love custard pies 😂

Here's last year's race. Let's hope this year's is equally exciting.

https://www.msn.com/en-gb/video/viral/london-pantomime-horse-race-2025-brits-take-part-in-bonkers-race-through-streets-of-greenwich/vi-AA1Skhjx

Phoenix, don't you mean Scancell is valued at approx £130m. rather than £300m?

Chief moaner vs Ripley

That's got to be a nil-nil draw 😂

Quite funny, but are sure it wasn't Mark talking to himself?

The Valirx clock has a special alarm to wake management up when a placing is due

Lindy has always had a strong following in the scientific community.

That's always what has kept me invested.

For example, project blueprint for the CRUK grand challenge.

Project Blueprint Team

Prof LG Durrant University of Nottingham Scancell Ltd., Nottingham

Prof Sahin TRON, Mainz BioNTech, Mainz

Prof Melief University of Leiden ISA pharmaceuticals, Leiden

Prof Mellman Genentech, South San Francisco

Prof Cerundulo University of Oxford

Prof Balachandran Memorial Sloan Kettering Cancer

Center, New York

Icahn School of Medicine at Mount

Sinai, New York

Prof de Vries Radboud University, Nijmegen

Prof Platten German Cancer Research Center,

Heidelberg

University Hospital Mannheim

Heidelberg University

Prof Rammensee Eberhard-Karls University Tuebingen

Dr Benham University of Durham

Prof Ottensmeier University of Southampton

Prof Jaeger National Center for Tumor Diseases

University Medical Center Heidelberg

German Cancer Research Center,

Heidelberg

Prof Pandurangan La Jolla Institute for Allergy & Immunology

Prof Mehanna University of Birmingham

C11

I will have you know that the mighty clarets will soon return stronger than ever 🤣

I agree Crusty, Genmab may await the first clinical results of at least one of the 2 mAbs under development before making a move on GT.

I would say the league table currently is:

iSCIB1

Modi1

GT

Just my opinion.

It perhaps stops ME receiving any letter bombs. A smart move 😂

29 recs for pater over the weekend

Val must be getting desperate

Bullet point production is just about ME's best talent. When in trouble, add another string to the Valirx bow.

His disciples follow suite 😂

"ValiRx has partnered with the University of Nottingham, providing in kind support for a recent £24,875 grant awarded through the University's Impact Acceleration Account (IAA) to support a 6-month feasibility program which will test feasibility and industrial relevance for a novel delivery platform for the Company's oncolytic peptide platform."

Haven't we had previous RNSs on the subject of peptide delivery using other methods. This paragraph seems to suggest the the delivery of CLX is still undecided.

So all is well with the world. Both the left side and the right side of the ratcliffewriter-RayPointer brain have replied.

UXM

You say:

"Not about the past. Clear milestones have been reached. Peer reviewed papers, invited editorials and an AACR slot prove CLX001 is the real deal."

The abstract does not mention CLX001, or am I missing something?

Thanks for spotting that Johnny

It is certainly a good sign that the advisory board is now international.

I think we are all probably frustrated by waiting for a deal.

However, this is possibly due to:

a) The number of interested parties

b) The possible variations in the type of deal (the principal variation may be an Immunobody deal versus an iSCIB1 deal)

From Sath's presentation, it looks to me that Scancell may be seeking a deal on Immunobody rather than iScib1 alone.

This was always Lindy's preference.

This season Valirx Lifestyle Academicals came bottom of division 3 of the Nottinghamshire Senior League.

When asked about next season's plans, manager Mark Eccleston stated "well, we just need to consolidate and see what next season brings".

A planned fans meeting was later abandoned as only two people turned up.